middle.news
Mesoblast Ryoncil sales accelerate as cash use drops sharply
10:15am on Friday 16th of October, 2026 AEDT
•
Biotechnology and Pharmaceuticals
Read Story
Mesoblast Ryoncil sales accelerate as cash use drops sharply
10:15am on Friday 16th of October, 2026 AEDT
Key Points
Ryoncil net revenue rose 44% to US$28 million
Net operating cash spend fell 85% to US$2.3 million
Cash balance stood at US$99 million at September 30
September delivered the highest monthly number of new patient starts
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Mesoblast (ASX:MSB)
OPEN ARTICLE